In the US, pembrolizumab and nivolumab (each in combination with CT) are approved for patients with GC/GEJC whose tumors express PD-L1 (CPS ≥ 1 for pembrolizumab; PD-L1 ≥ 1 for nivolumab) [16, 17]. The gene discussed is CD274; the disease is gastric cancer.